New drug for lung cancer has achieved more than expected results, with an objective response rate of 64%

New drug for lung cancer has achieved more than expected results, with an objective response rate of 64%

April 11, 2018 Source: WuXi PharmaTech

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

Today, Spectrum Pharmaceuticals, a biotechnology company specializing in hematology and oncology, published the latest data from a phase 2 study in the new drug poziotinib in EGFR exon 20 mutant non-small cell lung cancer (NSCLC), which was developed by the University of Texas MD. Leading scientist at the Anderson Cancer Center.

Lung cancer is the leading cause of cancer deaths worldwide, with more deaths per year than lung cancer, breast cancer and prostate cancer. Lung cancer is mainly divided into non-small cell lung cancer (NSCLC) and small cell lung cancer, of which NSCLC is the most common type, accounting for about 85% of all cases. In the United States, the five-year survival rate for lung cancer patients at all stages is 18%, and they urgently need new therapies to alleviate the disease and prolong life.

Poziotinib is a novel oral quinazoline broad-spectrum HER inhibitor that irreversibly blocks the signaling pathways of HER family tyrosine kinase receptors, including HER1, HER2 and HER4, thereby inhibiting tumor cells that overexpress these receptors. Proliferation. The drug is currently being studied in patients with lung cancer, breast cancer, stomach cancer and head and neck cancer.

In the study, Dr. John Heymach, director and professor of chest and head and neck oncology at MD Anderson Cancer Center, said that they were pleased to observe an objectively confirmed rate of remission of poziotinib in patients with EGFR exon 20 mutant NSCLC (ORR) And potential progression-free survival (PFS) benefits. Among the top 11 patients, the confirmed ORR was 64%, and their initial expected result was 20%-30%. To their encouragement, the median PFS of these 11 patients had not been reached after an average follow-up of 6.5 months. In addition, the two most common adverse events in the trial were rash and diarrhea, which are known to be associated with EGFR inhibitors. The full data for the study will be announced at a medical conference later this year.

â–²Poziotinib (Source: Spectrum Pharmaceuticals official website)

“The latest data from MD Anderson provides more insight into the possible implications of poziotinib in this highly unmet need area,” said Mr. Joe Turgeon, President and CEO of Spectrum. “This drug acts as an EGFR exon 20 The possibility of choice for patients with mutant NSCLC is becoming more and more clear."

"Our research at MD Anderson goes far beyond our enrollment expectations," said Dr. Xiuning Le, assistant professor of chest and head and neck oncology at MD Anderson Cancer Center. "So far, 30 EGFR patients in the original cohort have Fully enrolled, 20 patients in the expanded cohort are also about to complete the enrollment. As our study enrollment is nearing completion, we will soon begin recruiting patients for the ongoing multicenter Phase 2 study at Spectrum."

"These early data from MD Anderson suggest that poziotinib has the potential to have a meaningful impact on patients with limited treatment options," said Dr. David Chu, a cancer and blood specialist in New York. "As the East Coast of the ongoing multicenter Phase 2 study at Spectrum." One of the initial research sites, we have patients from all over the world to seek treatment. I am happy that these patients have this potential treatment option."

We expect this new drug to continue to achieve good results in subsequent research, bringing new treatment options for patients with lung cancer.

Reference materials:

[1] Spectrum Pharmaceuticals Announces Update of MD Anderson's Phase 2 Data Studying Poziotinib in EGFR Exon20 Mutant Non-Small Cell Lung Cancer Patients

[2] Spectrum Pharmaceuticals official website

Food Coloring Material

We are a professional Chinese manufacturer of Food Coloring Material Powder; we supply various products of Food Coloring Material, such as Phycocyanin Powder, Food Pigment, Food Colorant, Curcumin Powder, Beetroot Red Powder, and can providing product images and basic parameters with each Food Pigment. We have the perfect after-sales service and technical support. Please do not hesitate to contact us, Look forward to your cooperation!

Phycocyanin Powder,Food Pigment,Food Colorant,Curcumin Powder,Beetroot Red Powder

Xi'an Quanao Biotech Co., Ltd. , https://www.quanaobiotech.com